Shenouda Wessa, Thomas Dixon, Nabi Omar, Zachariah Seeba
College of Pharmacy, Gulf Medical University, Ajman, United Arab Emirates.
Operations, Thumbay University Hospital, Ajman, United Arab Emirates.
Front Pharmacol. 2025 Apr 1;16:1529528. doi: 10.3389/fphar.2025.1529528. eCollection 2025.
Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitors, known as Gliflozins, have demonstrated efficacy in managing type 2 diabetes mellitus (T2DM) and providing cardiovascular and renal benefits. Given the prevalence of diabetes, heart failure (HF), and chronic kidney disease (CKD) in the UAE, there is a need to evaluate the prescribing patterns of Gliflozins in these population. The objective of this study was to explore the relationship between Gliflozins use for patients who were admitted to the hospital at least once from 2021 to 2023 and different clinical factors.
A retrospective medication review was conducted from 2021 to 2023 at tertiary-level care hospital in Ajman, UAE. Data were collected on prescribed Gliflozins, patient demographic information, BMI, HbA1c levels, and comorbidities (HF, CKD). Chi-square tests and binary logistic regression were used to explore associations between Gliflozin use and clinical factors.
Out of the 255 patients' data collected, Gliflozin use was significantly associated with obesity (p = 0.002), higher HbA1c levels (p < 0.001), and comorbidities, particularly HF (61.5% of HF patients) and CKD. The use of Gliflozins increased each year. Patients with HF were 8.03 times more likely to use Gliflozins, and those with diabetes were 6.86 times more likely, underscoring the multidimensional role of these medications.
Gliflozin prescribing patterns in the UAE reflect global trends, with increased use among patients with diabetes, HF, and CKD. Further research is recommended to explore factors influencing prescription practices and optimize Gliflozin therapy if gliflozins use considerably increase in new diagnosis of diabetes and CKD even in mild conditions.
钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂，即格列净类药物，已证明在治疗2型糖尿病（T2DM）以及提供心血管和肾脏益处方面具有疗效。鉴于阿联酋糖尿病、心力衰竭（HF）和慢性肾脏病（CKD）的患病率，有必要评估这些人群中格列净类药物的处方模式。本研究的目的是探讨2021年至2023年期间至少入院一次的患者使用格列净类药物与不同临床因素之间的关系。
2021年至2023年在阿联酋阿治曼的一家三级护理医院进行了一项回顾性药物审查。收集了有关处方格列净类药物、患者人口统计学信息、体重指数（BMI）、糖化血红蛋白（HbA1c）水平和合并症（HF、CKD）的数据。使用卡方检验和二元逻辑回归来探讨格列净类药物使用与临床因素之间的关联。
在收集的255例患者数据中，格列净类药物的使用与肥胖（p = 0.002）、较高的HbA1c水平（p < 0.001）以及合并症显著相关，尤其是HF（HF患者中的61.5%）和CKD。格列净类药物的使用逐年增加。HF患者使用格列净类药物的可能性是其他患者的8.03倍，糖尿病患者使用的可能性是其他患者的6.86倍，这突出了这些药物的多维度作用。
阿联酋格列净类药物的处方模式反映了全球趋势，糖尿病、HF和CKD患者的使用量增加。建议进一步研究以探索影响处方实践的因素，并在糖尿病和CKD新诊断病例（即使是轻度病例）中格列净类药物使用量大幅增加的情况下优化格列净类药物治疗。
